Decision on future reimbursement status of losartan-containing medicines (C09CA01 and C09DA01) - angiotensin II antagonists
On 16 April 2010, the Danish Medicines Agency decided on the future reimbursement status of some of the losartan-containing medicines in ATC groups C09C and C09D, making these products eligible for general reimbursement as of 19 April 2010.
Via the factbox to the right, you can find a link to the decision and the letter which the Danish Medicines Agency has sent to companies holding a marketing authorisation for medicinal products comprised by the decision. All documents are in Danish.
For further information, please contact the Reimbursement Department at email@example.com.
Danish Medicines Agency, 19 April 2010